Acute Myeloid Leukemia (AML) is a rapid-progressing hematologic malignancy characterized by the uncontrolled proliferation of immature myeloid cells. Current cancer research focuses on understanding the genetic and molecular basis of AML to develop targeted therapies. Advances in genomics have identified mutations in genes such as FLT3, NPM1, and DNMT3A, providing insights into disease pathogenesis and potential therapeutic targets. Novel treatments, including FLT3 inhibitors and immune-based therapies like monoclonal antibodies and CAR-T cells, are under investigation. Additionally, researchers are exploring the role of the bone marrow microenvironment in AML progression and resistance to therapy, aiming to improve patient outcomes through personalized medicine.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : A case-based approach using IMPeTUs criteria in FDG PET/CT reporting of multiple myeloma
Mudalsha Ravina, All India Institute of Medical Sciences, India
Title : Transforming cancer care: Innovations, integrations, and impact
Shayan Maqsood, Jamia Hamdard University, India
Title : Updates on controversies surrounding the staging and management of newly diagnosed localized prostate cancer using prostate-specific membrane antigen (PSMA) positron emission tomography
Patricia Tai, University of Saskatchewan, Canada
Title : Advanced nanoparticles, the hallmark of targeted drug delivery for osteosarcoma
Shayan Maqsood, Jamia Hamdard University, India